Apriem Advisors buys $6,388,064 stake in Pfizer (PFE)

Pfizer (PFE) : Apriem Advisors scooped up 9,896 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 196,013 shares of Pfizer which is valued at $6,388,064.Pfizer makes up approximately 1.94% of Apriem Advisors’s portfolio.

Other Hedge Funds, Including , Wealthfront Inc boosted its stake in PFE in the latest quarter, The investment management firm added 920 additional shares and now holds a total of 78,205 shares of Pfizer which is valued at $2,532,278. Pfizer makes up approx 0.07% of Wealthfront Inc’s portfolio.Cam Group Holding As reduced its stake in PFE by selling 440,000 shares or 38.3% in the most recent quarter. The Hedge Fund company now holds 708,915 shares of PFE which is valued at $21,189,469. Pfizer makes up approx 0.40% of Cam Group Holding As’s portfolio.Tdam Usa reduced its stake in PFE by selling 14,919 shares or 5.0% in the most recent quarter. The Hedge Fund company now holds 283,240 shares of PFE which is valued at $8,675,641. Pfizer makes up approx 0.44% of Tdam Usa’s portfolio.Fiduciary Group boosted its stake in PFE in the latest quarter, The investment management firm added 581 additional shares and now holds a total of 138,159 shares of Pfizer which is valued at $4,459,773. Pfizer makes up approx 1.23% of Fiduciary Group’s portfolio.Ifc Holdings Incorporatedfl reduced its stake in PFE by selling 736 shares or 1.09% in the most recent quarter. The Hedge Fund company now holds 66,651 shares of PFE which is valued at $2,141,497. Pfizer makes up approx 0.23% of Ifc Holdings Incorporatedfl’s portfolio.

Pfizer closed down -0.25 points or -0.79% at $31.48 with 2,41,56,427 shares getting traded on Monday. Post opening the session at $31.95, the shares hit an intraday low of $31.44 and an intraday high of $31.95 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Pfizer reported $0.61 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on Nov 1, 2016. Analyst had a consensus of $0.62. The company had revenue of $13045.00 million for the quarter, compared to analysts expectations of $13027.62 million. The company’s revenue was up 7.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.60 EPS.

Many Wall Street Analysts have commented on Pfizer. Pfizer was Downgraded by Argus to ” Hold” on Nov 2, 2016. Pfizer was Downgraded by Jefferies to ” Hold” on Oct 13, 2016.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.